Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adsorbed acellular diphtheria-tetanus-pertussis and inactivated poliomyelitis combined vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The adsorbed acellular diphtheria-tetanus-pertussis and inactivated poliomyelitis combined vaccine (DTaP-sIPV) is a quadrivalent combination vaccine designed to provide active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. This specific formulation, being evaluated in clinical trials in China, incorporates the Sabin strain for its inactivated poliovirus (sIPV) component, distinguishing it from traditional Salk-strain IPV vaccines. The vaccine is adsorbed onto an aluminum-based adjuvant to enhance the immune response and is administered via intramuscular injection. It is primarily intended for use in infants and young children, with clinical studies assessing its safety and immunogenicity in populations aged 2 months to 6 years.
- Other names
- DTaP-sIPV vaccineadsorbed acellular diphtheria-tetanus-pertussis and inactivated poliovirus (Sabin strain) combined vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on adsorbed acellular diphtheria-tetanus-pertussis and inactivated poliomyelitis combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adsorbed acellular diphtheria-tetanus-pertussis and inactivated poliomyelitis combined vaccine.